{
    "name": "cabergoline",
    "comment": "Rx",
    "other_names": [
        "Dostinex"
    ],
    "classes": [
        "Hyperprolactinemia"
    ],
    "source": "https://reference.medscape.com/drug/dostinex-cabergoline-342876",
    "pregnancy": {
        "common": [
            "Pregnancy Category: B",
            "Lactation: excretion in milk unknown; not recommended"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: excretion in milk unknown; not recommended"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Uncontrolled hypertension",
                "Hypersensitivity to ergot derivatives",
                "Severe hepatic disease",
                "Concurrent use with D2 antagonists",
                "History of pulmonary, pericardial, or retroperitoneal fibroti disorders",
                "Women planning to nurse",
                "History of cardiac valvular disorders as suggested by anatomical evidence of valvulopathy of any valve, determined by pretreatment evaluation including echocardiographic demonstration of valve leaflet thickening, valve restriction, or mixed valve restriction-stenosis"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Initial doses >1 mg may produce orthostatic hypotension",
                "Concomitant antihypertensives",
                "May cause somnolence; avoid performing tasks that require mental alertness",
                "Reportedly can cause cardiac damage",
                "May cause orthostatic hypotension; avoid concurrent use with antihypertensives",
                "Rare cases of retroperitoneal fibrosis reported",
                "Hepatic impairment",
                "Inhibits lactation",
                "Impulse control/compulsive behaviors reported in patients receiving therapy; this has been generally reversible upon reduction of dose or treatment discontinuation; prescribers should consider dose reduction or stopping medication if a patient develops such urges while receiving therapy"
            ],
            "specific": [
                {
                    "type": "Valvular disease",
                    "description": [
                        "All patients should undergo a cardiovascular evaluation, including echocardiogram to assess the potential presence of valvular disease; if valvular disease is detected, the patient should not be treated with cabergoline",
                        "Following treatment initiation, clinical and diagnostic monitoring (for example, chest x-ray, CT scan and cardiac echocardiogram) should be conducted to assess the risk of cardiac valvulopathy",
                        "Discontinue if an echocardiogram reveals new valvular regurgitation, valvular restriction or valve leaflet thickening"
                    ]
                }
            ]
        }
    },
    "interactions": [
        {
            "classification_type": "Contraindicated",
            "interaction_with": "almotriptan",
            "description": {
                "common": "cabergoline, almotriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "eletriptan",
            "description": {
                "common": "cabergoline, eletriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "frovatriptan",
            "description": {
                "common": "cabergoline, frovatriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "glyceryl trinitrate pr",
            "description": {
                "common": "cabergoline decreases effects of glyceryl trinitrate pr by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "naratriptan",
            "description": {
                "common": "cabergoline, naratriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nitroglycerin IV",
            "description": {
                "common": "cabergoline decreases effects of nitroglycerin IV by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nitroglycerin sublingual",
            "description": {
                "common": "cabergoline decreases effects of nitroglycerin sublingual by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nitroglycerin topical",
            "description": {
                "common": "cabergoline decreases effects of nitroglycerin topical by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nitroglycerin transdermal",
            "description": {
                "common": "cabergoline decreases effects of nitroglycerin transdermal by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "nitroglycerin translingual",
            "description": {
                "common": "cabergoline decreases effects of nitroglycerin translingual by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "rizatriptan",
            "description": {
                "common": "cabergoline, rizatriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sumatriptan",
            "description": {
                "common": "cabergoline, sumatriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "sumatriptan intranasal",
            "description": {
                "common": "cabergoline, sumatriptan intranasal.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Contraindicated",
            "interaction_with": "zolmitriptan",
            "description": {
                "common": "cabergoline, zolmitriptan.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Additive vasospasm.  Sep. by 24h."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "amyl nitrite",
            "description": {
                "common": "amyl nitrite increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "aripiprazole",
            "description": {
                "common": "aripiprazole decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "atazanavir",
            "description": {
                "common": "atazanavir increases levels of cabergoline by decreasing metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benperidol",
            "description": {
                "common": "benperidol decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "benzphetamine",
            "description": {
                "common": "cabergoline, benzphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "bromocriptine",
            "description": {
                "common": "cabergoline, bromocriptine.\nEither increases toxicity of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. The concomitant use of bromocriptine with ergot alkaloids may potentially lead to ergot toxicity; therefore the combination should be avoided."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "chlorpromazine",
            "description": {
                "common": "chlorpromazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clarithromycin",
            "description": {
                "common": "clarithromycin increases levels of cabergoline by decreasing metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "clozapine",
            "description": {
                "common": "clozapine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "darunavir",
            "description": {
                "common": "darunavir increases levels of cabergoline by decreasing metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexfenfluramine",
            "description": {
                "common": "dexfenfluramine, cabergoline.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Risk of serotonin syndrome."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dexmethylphenidate",
            "description": {
                "common": "cabergoline, dexmethylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dextroamphetamine",
            "description": {
                "common": "cabergoline, dextroamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "diethylpropion",
            "description": {
                "common": "cabergoline, diethylpropion. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dobutamine",
            "description": {
                "common": "cabergoline, dobutamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "dopamine",
            "description": {
                "common": "cabergoline, dopamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "droperidol",
            "description": {
                "common": "droperidol decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "efavirenz",
            "description": {
                "common": "efavirenz increases levels of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Competitive inhibition of CYP3A4 might lead to vasospasm and ischemia."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ephedrine",
            "description": {
                "common": "cabergoline, ephedrine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "epinephrine",
            "description": {
                "common": "cabergoline, epinephrine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fenfluramine",
            "description": {
                "common": "fenfluramine, cabergoline.\nEither increases toxicity of the other by pharmacodynamic synergism. Contraindicated. Risk of serotonin syndrome."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fluphenazine",
            "description": {
                "common": "fluphenazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "fosamprenavir",
            "description": {
                "common": "fosamprenavir increases levels of cabergoline by decreasing metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "glyceryl trinitrate pr",
            "description": {
                "common": "glyceryl trinitrate pr increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "haloperidol",
            "description": {
                "common": "haloperidol decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "iloperidone",
            "description": {
                "common": "iloperidone decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "indinavir",
            "description": {
                "common": "indinavir increases levels of cabergoline by decreasing metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isoproterenol",
            "description": {
                "common": "cabergoline, isoproterenol. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isosorbide dinitrate",
            "description": {
                "common": "isosorbide dinitrate increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "isosorbide mononitrate",
            "description": {
                "common": "isosorbide mononitrate increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "lisdexamfetamine",
            "description": {
                "common": "cabergoline, lisdexamfetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "loxapine",
            "description": {
                "common": "loxapine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "loxapine inhaled",
            "description": {
                "common": "loxapine inhaled decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methamphetamine",
            "description": {
                "common": "cabergoline, methamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylenedioxymethamphetamine",
            "description": {
                "common": "cabergoline, methylenedioxymethamphetamine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "methylphenidate",
            "description": {
                "common": "cabergoline, methylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide",
            "description": {
                "common": "metoclopramide decreases levels of cabergoline by inhibition of GI absorption. Applies only to oral form of both agents. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "metoclopramide intranasal",
            "description": {
                "common": "metoclopramide intranasal, cabergoline. dopaminergic effects. Avoid or Use Alternate Drug. Opposing effects of metoclopramide and the interacting drug on dopamine. Potential exacerbation of symptoms (eg, parkinsonian symptoms) or decreased therapeutic effects of metoclopramide."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "midodrine",
            "description": {
                "common": "cabergoline, midodrine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nelfinavir",
            "description": {
                "common": "nelfinavir increases levels of cabergoline by decreasing metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nicorandil",
            "description": {
                "common": "nicorandil increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nitroglycerin IV",
            "description": {
                "common": "nitroglycerin IV increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nitroglycerin PO",
            "description": {
                "common": "nitroglycerin PO increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nitroglycerin sublingual",
            "description": {
                "common": "nitroglycerin sublingual increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nitroglycerin topical",
            "description": {
                "common": "nitroglycerin topical increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nitroglycerin transdermal",
            "description": {
                "common": "nitroglycerin transdermal increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "nitroglycerin translingual",
            "description": {
                "common": "nitroglycerin translingual increases effects of cabergoline by decreasing metabolism. Avoid or Use Alternate Drug. Risk of increased SBP, angina pectoris."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "norepinephrine",
            "description": {
                "common": "cabergoline, norepinephrine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "olanzapine",
            "description": {
                "common": "olanzapine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "paliperidone",
            "description": {
                "common": "paliperidone decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "perphenazine",
            "description": {
                "common": "perphenazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phendimetrazine",
            "description": {
                "common": "cabergoline, phendimetrazine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phentermine",
            "description": {
                "common": "cabergoline, phentermine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenylephrine",
            "description": {
                "common": "cabergoline, phenylephrine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "phenylephrine PO",
            "description": {
                "common": "cabergoline, phenylephrine PO. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pimozide",
            "description": {
                "common": "pimozide decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "prochlorperazine",
            "description": {
                "common": "prochlorperazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "promethazine",
            "description": {
                "common": "promethazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "propylhexedrine",
            "description": {
                "common": "cabergoline, propylhexedrine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "pseudoephedrine",
            "description": {
                "common": "cabergoline, pseudoephedrine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "quetiapine",
            "description": {
                "common": "quetiapine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "risperidone",
            "description": {
                "common": "risperidone decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ritonavir",
            "description": {
                "common": "ritonavir increases levels of cabergoline by decreasing metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "saquinavir",
            "description": {
                "common": "saquinavir increases levels of cabergoline by decreasing metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "serdexmethylphenidate/dexmethylphenidate",
            "description": {
                "common": "cabergoline, serdexmethylphenidate/dexmethylphenidate. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thioridazine",
            "description": {
                "common": "thioridazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "thiothixene",
            "description": {
                "common": "thiothixene decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "tipranavir",
            "description": {
                "common": "tipranavir increases levels of cabergoline by decreasing metabolism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "trifluoperazine",
            "description": {
                "common": "trifluoperazine decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "xylometazoline",
            "description": {
                "common": "cabergoline, xylometazoline. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "yohimbine",
            "description": {
                "common": "cabergoline, yohimbine. Mechanism: pharmacodynamic synergism. Contraindicated. Additive vasospasm; risk of hypertension."
            }
        },
        {
            "classification_type": "Serious",
            "interaction_with": "ziprasidone",
            "description": {
                "common": "ziprasidone decreases effects of cabergoline by pharmacodynamic antagonism. Contraindicated."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "apomorphine",
            "description": {
                "common": "apomorphine and cabergoline both increase  dopaminergic effects. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "bromocriptine",
            "description": {
                "common": "bromocriptine and cabergoline both increase  dopaminergic effects. Use Caution/Monitor. Combining drugs may be therapeutic in patients with Parkinsonism. "
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "dopamine",
            "description": {
                "common": "cabergoline and dopamine both increase  dopaminergic effects. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lisuride",
            "description": {
                "common": "cabergoline and lisuride both increase  dopaminergic effects. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "lurasidone",
            "description": {
                "common": "lurasidone, cabergoline.\nEither decreases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Antipsychotics may diminish  the therapeutic effect of anti-parkinson's agents; may increase risk if hypotension."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "methyldopa",
            "description": {
                "common": "cabergoline and methyldopa both increase  dopaminergic effects. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "pramipexole",
            "description": {
                "common": "cabergoline and pramipexole both increase  dopaminergic effects. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ropinirole",
            "description": {
                "common": "cabergoline and ropinirole both increase  dopaminergic effects. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "solriamfetol",
            "description": {
                "common": "cabergoline and solriamfetol both increase  sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Use Caution/Monitor."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Nausea",
            "percent": "27"
        },
        {
            "name": "Headache",
            "percent": "26"
        },
        {
            "name": "Dizziness",
            "percent": "15"
        },
        {
            "name": "Asthenia",
            "percent": "9"
        },
        {
            "name": "Fatigue",
            "percent": "7"
        },
        {
            "name": "Abdominal pain",
            "percent": "5"
        },
        {
            "name": "Somnolence",
            "percent": "5"
        },
        {
            "name": "Postural hypotension",
            "percent": "4"
        },
        {
            "name": "Depression",
            "percent": "3"
        },
        {
            "name": "Dyspepsia",
            "percent": "2"
        },
        {
            "name": "Nervousness",
            "percent": "2"
        },
        {
            "name": "Abnormal vision",
            "percent": "1"
        },
        {
            "name": "Breast pain",
            "percent": "1"
        },
        {
            "name": "Dysmenorrhea",
            "percent": "1"
        },
        {
            "name": "Hot flashes",
            "percent": "1"
        },
        {
            "name": "Paresthesia",
            "percent": "1"
        },
        {
            "name": "Constipation",
            "percent": "10"
        },
        {
            "name": "Aggression",
            "percent": null
        },
        {
            "name": "Fibrosis",
            "percent": null
        },
        {
            "name": "Gastric ulcer",
            "percent": null
        },
        {
            "name": "Valvulopathy",
            "percent": null
        },
        {
            "name": "Gastric ulcer",
            "percent": null
        },
        {
            "name": "Pleural effusion",
            "percent": null
        },
        {
            "name": "Psychosis",
            "percent": null
        },
        {
            "name": "Impulse control",
            "percent": null
        },
        {
            "name": "compulsive behavior symptoms",
            "percent": null
        },
        {
            "name": "including hypersexuality",
            "percent": null
        },
        {
            "name": "increased libido and pathological gambling",
            "percent": null
        }
    ]
}